209 related articles for article (PubMed ID: 11176403)
1. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens.
Di Stasi SM; Giannantoni A; Vespasiani G; Navarra P; Capelli G; Massoud R; Stephen RL
J Urol; 2001 Feb; 165(2):491-8. PubMed ID: 11176403
[TBL] [Abstract][Full Text] [Related]
2. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin.
Di Stasi SM; Giannantoni A; Navarra P; Capelli G; Storti L; Porena M; Stephen RL
J Urol; 2001 Dec; 166(6):2232-6. PubMed ID: 11696741
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
[TBL] [Abstract][Full Text] [Related]
4. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride.
Madersbacher H; Jilg G
Paraplegia; 1991 Feb; 29(2):84-90. PubMed ID: 2023781
[TBL] [Abstract][Full Text] [Related]
5. Electromotive administration of oxybutynin into the human bladder wall.
Di Stasi SM; Giannantoni A; Massoud R; Cortese C; Vespasiani G; Micali F
J Urol; 1997 Jul; 158(1):228-33. PubMed ID: 9186365
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P
J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic effects of intrarectal administration of oxybutynin].
Radziszewski P; Borkowski A
Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351
[TBL] [Abstract][Full Text] [Related]
8. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M
Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
[TBL] [Abstract][Full Text] [Related]
9. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population.
Palmer LS; Zebold K; Firlit CF; Kaplan WE
J Urol; 1997 Feb; 157(2):638-40. PubMed ID: 8996387
[TBL] [Abstract][Full Text] [Related]
10. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
[TBL] [Abstract][Full Text] [Related]
11. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
Davila GW; Daugherty CA; Sanders SW;
J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
[TBL] [Abstract][Full Text] [Related]
12. [Topical administration of oxybutynin hydrochloride in women with urge incontinence. Results of a prospective randomized double-blind study].
Enzelsberger H; Kurz C; Helmer H; Mittermayer F
Geburtshilfe Frauenheilkd; 1995 May; 55(5):240-3. PubMed ID: 7607378
[TBL] [Abstract][Full Text] [Related]
13. Intravesical oxybutynin: practicalities of clinical use.
Guerrero K; Emery S; Owen L; Rowlands M
J Obstet Gynaecol; 2006 Feb; 26(2):141-3. PubMed ID: 16483973
[TBL] [Abstract][Full Text] [Related]
14. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury.
Pannek J; Sommerfeld HJ; Bötel U; Senge T
Urology; 2000 Mar; 55(3):358-62. PubMed ID: 10699610
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction.
Franco I; Horowitz M; Grady R; Adams RC; de Jong TP; Lindert K; Albrecht D
J Urol; 2005 Jan; 173(1):221-5. PubMed ID: 15592080
[TBL] [Abstract][Full Text] [Related]
16. Electromotive administration of intravesical bethanechol and the clinical impact on acontractile detrusor management: introduction of a new test.
Riedl CR; Stephen RL; Daha LK; Knoll M; Plas E; Pflüger H
J Urol; 2000 Dec; 164(6):2108-11. PubMed ID: 11061937
[TBL] [Abstract][Full Text] [Related]
17. Treatment with modified intravesical oxybutynin chloride for neurogenic bladder in children.
Hayashi A; Saito M; Okada S; Hanada T; Watanabe T; Satoh K; Kanzaki S
J Pediatr Urol; 2007 Dec; 3(6):438-42. PubMed ID: 18947791
[TBL] [Abstract][Full Text] [Related]
18. Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia.
Painter KA; Vates TS; Bukowski TP; Fleming P; Freedman AL; Smith CA; Gonzalez R; Perlmutter AD
J Urol; 1996 Oct; 156(4):1459-62. PubMed ID: 8808907
[TBL] [Abstract][Full Text] [Related]
19. Treatment of overactive bladder with modified intravesical oxybutynin chloride.
Saito M; Tabuchi F; Otsubo K; Miyagawa I
Neurourol Urodyn; 2000; 19(6):683-8. PubMed ID: 11071699
[TBL] [Abstract][Full Text] [Related]
20. Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self)catheterisation and optimized intravesical oxybutynin hydrochloride therapy.
Buyse G; Verpoorten C; Vereecken R; Casaer P
Eur J Pediatr Surg; 1995 Dec; 5 Suppl 1():31-4. PubMed ID: 8770576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
